BTN2A1 and nasopharyngeal carcinoma: Here, we demonstrated that the EBV gene BRRF1, which can be triggered by an EBV-targeting probe (P4), upregulates the expression of BTN2A1 with the potential to support Vγ9Vδ2 T-cell adoptive immunotherapy against NPC.